Paul Edwards
Sab Member @Imophoron Ltd
Signup · Get unlimited contacts
WORK HISTORY
Sab Member @Imophoron Ltd
Imophoron is a pre-clinical stage company with a novel vaccine platform called ADDomer. ADDomer is a patented technology for creating highly immunogenic vaccine candidates and is an adenovirus-derived, multimeric protein-based, self-assembling nanoparticle scaffold. Proof of concept data for two highly infectious diseases demonstrate potential to prevent disease and transmission.
EDUCATION
University of Surrey
B.Sc., Chemistry
ABOUT PAUL EDWARDS
Paul has over 40 years experience in the pharmaceutical and life science arena. A graduate chemist, he initially worked for Beecham Pharmaceuticals and Genzyme Corporation, where he headed the UK operations for the company. In he joined the UK based biosimilars’ organisation, GeneMedix plc as Chief Executive Officer, and successfully led a major funding round taking the company to a dual listing on the London and Singapore Stock Exchanges. More recently, Paul has acted as a NED to Goldshield Group plc and BioProducts Laboratories and oversaw the sale of both organisations to Private Equity Groups. He acted as interim CEO to NanoMab Technology Ltd as well as serving as Managing Partner and board member of the global Executive Search Group, Horton International. Paul is a familiar face in the UK biotech arena, having been the Chairman of the UK BioIndustry Association’s Manufacturing Advisory Committee and was the recipient of the Donald Medal for services to Biochemical Engineering Since 2021, he has been a non-Executive Director of OBN, representing over 400 members companies in the UK Life Science sector. Paul has recently become the Executive Chair of IsomAb Ltd, a spin-out company from the University of Nottingham as well as a SAB member for Imophoron Ltd. In 1997 he received an MBE for services to biotechnology.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.